Benitec Biopharma (BNTC) FCF Margin (2019 - 2023)

Benitec Biopharma has reported FCF Margin for 5 years, with the latest figure at 58342.86% in Q2 2023.

• Quarterly FCF Margin changed N/A year-over-year to 58342.86% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 288485.71% (down 26079454.0% YoY) and the FY2023 annual result came in at 24001.33%, down 220270.0% from the prior year.
• FCF Margin eased to 58342.86% in Q2 2023 per BNTC's latest filing, from 7438.89% in the prior quarter.
• Over five years, FCF Margin peaked at 9022.86% in Q2 2020 and troughed at 346000.0% in Q4 2020.
• A 5-year average of 71471.89% and a median of 7438.89% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2020 and 2021: FCF Margin plunged 34200519 bps in 2020, then soared 33280000 bps in 2021.
• Over 5 years, FCF Margin stood at 3994.81% in 2019, then sank by 8561 bps to 346000.0% in 2020, then surged by 96 bps to 13200.0% in 2021, then sank by 217 bps to 41821.43% in 2022, then plunged by 40 bps to 58342.86% in 2023.
• According to Business Quant data, FCF Margin over the past three periods registered 58342.86%, 7438.89%, and 41821.43% for Q2 2023, Q1 2023, and Q4 2022 respectively.